According to Alexandria Real Estate Equities 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.6140. At the end of 2025 the company had a P/S ratio of 5.45.
Year | P/S ratio | Change |
---|---|---|
2025 | 5.45 | -3.33% |
2024 | 5.64 | -27.28% |
2023 | 7.75 | -16.47% |
2022 | 9.28 | -44.49% |
2021 | 16.7 | 30.53% |
2020 | 12.8 | -0.49% |
2019 | 12.9 | 32.25% |
2018 | 9.73 | -13.23% |
2017 | 11.2 | 14.08% |
2016 | 9.83 | 22.88% |
2015 | 8.00 | -9.14% |
2014 | 8.80 | 20.55% |
2013 | 7.30 | 0.05% |
2012 | 7.30 | -14.75% |
2011 | 8.56 | -2.37% |
2010 | 8.77 | 21.13% |
2009 | 7.24 | 39.2% |
2008 | 5.20 | -48.94% |
2007 | 10.2 | -14.54% |
2006 | 11.9 | 26.22% |
2005 | 9.44 | 0.05% |
2004 | 9.44 | 12.4% |
2003 | 8.40 | 21.7% |
2002 | 6.90 | 1.27% |
2001 | 6.81 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
![]() Pfizer PFE | 2.21 | -50.24% | ๐บ๐ธ USA |
![]() Gilead Sciences GILD | 4.89 | 10.03% | ๐บ๐ธ USA |
![]() Eli Lilly LLY | 14.8 | 232.90% | ๐บ๐ธ USA |
![]() Illumina ILMN | 4.01 | -9.82% | ๐บ๐ธ USA |
![]() Bristol-Myers Squibb BMY | 2.03 | -54.36% | ๐บ๐ธ USA |
![]() Amgen AMGN | 4.75 | 6.75% | ๐บ๐ธ USA |
![]() Alnylam Pharmaceuticals
ALNY | 18.0 | 305.55% | ๐บ๐ธ USA |